[go: up one dir, main page]

MX2016004445A - Stable triflusal powder formulation for oral administration and method of preparation thereof. - Google Patents

Stable triflusal powder formulation for oral administration and method of preparation thereof.

Info

Publication number
MX2016004445A
MX2016004445A MX2016004445A MX2016004445A MX2016004445A MX 2016004445 A MX2016004445 A MX 2016004445A MX 2016004445 A MX2016004445 A MX 2016004445A MX 2016004445 A MX2016004445 A MX 2016004445A MX 2016004445 A MX2016004445 A MX 2016004445A
Authority
MX
Mexico
Prior art keywords
triflusal
oral administration
stable
preparation
powder formulation
Prior art date
Application number
MX2016004445A
Other languages
Spanish (es)
Inventor
Evangelos Karavas
Efthimios Koutris
Vicky Samara
Amalia Diakidou
Louiza Konstanti
Original Assignee
Expermed S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Expermed S A filed Critical Expermed S A
Publication of MX2016004445A publication Critical patent/MX2016004445A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

The present invention relates to a dispersible pharmaceutical formulation in the form of granules for oral administration comprising Triflusal together with at least one pharmaceutically acceptable excipient and a method for manufacturing thereof.
MX2016004445A 2013-10-10 2013-10-10 Stable triflusal powder formulation for oral administration and method of preparation thereof. MX2016004445A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/003039 WO2015051811A1 (en) 2013-10-10 2013-10-10 Stable triflusal powder formulation for oral administration and method of preparation thereof

Publications (1)

Publication Number Publication Date
MX2016004445A true MX2016004445A (en) 2016-07-21

Family

ID=49474361

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004445A MX2016004445A (en) 2013-10-10 2013-10-10 Stable triflusal powder formulation for oral administration and method of preparation thereof.

Country Status (4)

Country Link
EP (1) EP3054922A1 (en)
KR (1) KR20160067175A (en)
MX (1) MX2016004445A (en)
WO (1) WO2015051811A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011036533A1 (en) * 2009-09-23 2011-03-31 Glenmark Pharmaceuticals Limited Pharmaceutical composition comprising prasugrel and triflusal
ES2389348B1 (en) * 2011-04-05 2013-09-23 Simbec Ibérica Sl TRIFLUSAL COMPOSITE POWDER, USE OF THE SAME FOR GRANULATES, COMPRESSED OR ENVELOPES, PROCEDURE FOR THE PREPARATION OF SUCH COMPOSITE POWDER AND USE OF ONE OR MORE CYCLODEXTRINES TO STABILIZE THE TRIFLUSAL.

Also Published As

Publication number Publication date
KR20160067175A (en) 2016-06-13
WO2015051811A1 (en) 2015-04-16
EP3054922A1 (en) 2016-08-17

Similar Documents

Publication Publication Date Title
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
PL3003285T3 (en) Solid pharmaceutical dosage form for release of at least two active pharmaceutical ingredients in the oral cavity
ZA201509239B (en) Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
PH12016500043A1 (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-andrenergic for administration by inhalation
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
ZA201405756B (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
HUE040666T2 (en) Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d
IL240666A0 (en) Pharmaceutical compositions for oral delivery and uses thereof
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
IL239958A (en) Chewable composition for oral administration and process for preparation thereof
WO2014167579A3 (en) Stable pharmaceutical compositions of tadalafil
PL3369429T3 (en) Pharmaceutical composition intended to be administered to nasal mucosa
MX2012013178A (en) Broad-spectrum anti-parasitic composition consisting of nitazoxanide, probiotics and prebiotics.
MX2014006201A (en) Imatinib solid dosage forms reconstituted just before use.
EP3381467A4 (en) Vaccine pharmaceutical composition for oral administration and method for manufacturing vaccine pharmaceutical composition for oral administration
EP3010534A4 (en) Pharmaceutical formulations and methods for oral delivery of biologically active ingredient
MX2015015681A (en) Pharmaceutical composition comprising fingolimod.
MX2016004445A (en) Stable triflusal powder formulation for oral administration and method of preparation thereof.
EP2979698A4 (en) Pharmaceutical composition for oral administration
ZA201500411B (en) Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, tablets thus obtained and their preparation process
PL2988782T3 (en) Dosage forms for oral administration of active substances
WO2013109213A3 (en) Pharmaceutical formulations comprising tiotropium